Treatment of high-risk neuroblastoma
Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trial...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
The Korean Pediatric Society
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346833/ |